Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,833.60 | 4.90 | 0.06% |
CAC 40 | 7,753.24 | 14.82 | 0.19% |
DAX 40 | 23,881.93 | 91.82 | 0.39% |
Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
FTSE 100 | 8,824.31 | 49.62 | 0.57% |
HKSE | 24,069.94 | 151.47 | -0.63% |
NASDAQ | 20,393.13 | 190.24 | 0.94% |
Nikkei 225 | 39,785.90 | 23.42 | 0.06% |
NZX 50 Index | 12,704.48 | 79.81 | -0.62% |
S&P 500 | 6,227.42 | 0.00 | 0.00% |
S&P/ASX 200 | 8,595.80 | 1.90 | -0.02% |
SSE Composite Index | 3,461.15 | 6.36 | 0.18% |